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Abstract
Background and Aims: The standard whole-colon tests used to investigate patients with
symptoms of colorectal cancer are barium enema and colonoscopy. Colonoscopy is the reference
test but is technically difficult, resource intensive, and associated with adverse events, especially in
the elderly. Barium enema is safer but has reduced sensitivity for cancer. CT colonography ("virtual
colonoscopy") is a newer alternative that may combine high sensitivity for cancer with safety and
patient acceptability. The SIGGAR trial aims to determine the diagnostic efficacy, acceptability, and
economic costs associated with this new technology.
Methods: The SIGGAR trial is a multi-centre randomised comparison of CT colonography versus
standard investigation (barium enema or colonoscopy), the latter determined by individual clinician
preference. Diagnostic efficacy for colorectal cancer and colonic polyps measuring 1 cm or larger
will be determined, as will the physical and psychological morbidity associated with each diagnostic
test, the latter via questionnaires developed from qualitative interviews. The economic costs of
making or excluding a diagnosis will be determined for each diagnostic test and information from
the trial and other data from the literature will be used to populate models framed to summarise
the health effects and costs of alternative approaches to detection of significant colonic neoplasia
in patients of different ages, prior risks and preferences. This analysis will focus particularly on the
frequency, clinical relevance, costs, and psychological and physical morbidity associated with
detection of extracolonic lesions by CT colonography.
Results: Recruitment commenced in March 2004 and at the time of writing (July 2007) 5025
patients have been randomised. A lower than expected prevalence of end-points in the barium
enema sub-trial has caused an increase in sample size. In addition to the study protocol, we describe
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our approach to recruitment, notably the benefits of extensive piloting, the use of a sham-
randomisation procedure, which was employed to determine whether centres interested in
participating were likely to be effective in practice, and the provision of funding for dedicated
sessions for a research nurse at each centre to devote specifically to this trial.
Trial registration: Current Controlled Trials ISRCTN95152621
Background
Computed tomographic colonography (CTC) is a rela-
tively novel health technology used to examine the large
bowel. Specifically, it combines helical CT scanning of the
cleansed and distended colorectum with complex image
rendering techniques, and is used primarily to detect
colorectal neoplasia. CTC was first described in 1994 [1]
and has been evaluated by several comparisons with
colonoscopy, both single-centre [2,3] and multi-centre
[4,5]. Meta-analysis of studies where patients have both
CTC and colonoscopy suggests that CTC has high average
sensitivity and specificity for diagnosis of colorectal neo-
plasia [6,7]. There are no randomised studies. Radiolo-
gists have repeatedly stressed a role in colorectal cancer
screening, with claims that CTC combines excellent sensi-
tivity for adenomatous polyps (the precursor of colorectal
cancer) with safety and acceptability [8]. However, at the
time of writing only a single published study has exam-
ined a representative sample [9] and the overwhelming
majority of studies have been exclusively based on
patients with symptoms suggestive of cancer. While these
studies have made a case for screening by focussing on the
detection of polyps, in reality polyps in these patients are
serendipitous findings and not responsible for symptoms.
The emphasis on polyps has obscured evidence that the
sensitivity of CTC for colorectal cancer is possibly as high
as colonoscopy and likely higher than barium enema, the
standard tests currently used for diagnosis. A recent meta-
analysis found an average sensitivity for cancer of 96%
(95%CI, 91% to 99%) [6]. It follows that the role of CTC
for diagnosis of symptomatic cancer deserves more atten-
tion.
Around 363,000 cases of colorectal cancer occur each year
in the European Union and 148,000 in the USA [10]. It is
important to make an early diagnosis because prognosis
depends on tumour stage but local variations in clinical
practice can delay this [11]. English patients with symp-
toms suggestive of colorectal cancer must be now be seen
by a specialist within 2-weeks of referral by their general
practitioner [12]. A "whole-colon" test is frequently
requested to search for cancer but because the "suggestive
symptoms" are non-specific and common in the general
population (e.g. abdominal pain, change in bowel habit),
most patients investigated do not have the disease. Colon-
oscopy is the most sensitive test but is expensive, resource
intensive, technically difficult, and has a small but well-
recognised morbidity and even mortality [13]. Further-
more, most patients investigated are elderly, the group
most at risk from adverse events. Barium enema is safer
than colonoscopy [14] but has reduced sensitivity [15],
and interpretation skills are declining [16]. CTC is safer
than colonoscopy [17,18] while being more sensitive
than barium enema, and appears to be more acceptable to
patients than either of the other tests [8]. CTC may also be
performed by technicians and in principle the data could
be read by computer-assistance [19], accelerating diagno-
sis and throughput.
The paragraphs above make the case that CTC may com-
bine accurate diagnosis of colorectal cancer with safety
and efficiency but CTC also presents the opportunity to
investigate other intra-abdominal organs (unlike colonos-
copy and barium enema) because these are included on
the scan. Pathology outside the colon may sometimes
underpin patients' symptoms and it is possible that CTC
could have more diagnostic utility overall than tests
restricted to the colorectum. However, characterisation of
extra-colonic findings may also consume significant
health-care resources investigating 'abnormalities' that
ultimately prove insignificant: A recent study found that
116 (52%) of 225 symptomatic patients studied by CTC
had one or more extracolonic findings, consuming
£34,329 to pursue – a figure exceeding the original costs
of CTC and effectively doubling investigation costs overall
[20]. It is unknown how these costs, along with inconven-
ience, anxiety, morbidity and occasionally even mortality,
are offset by the benefit to those with sub-clinical but
potentially lethal diseases. CTC will also serendipitously
detect significant adenomatous polyps (defined as 1 cm or
lager in size) that are not responsible for symptoms but
which, having been detected, will need endoscopic
removal.
In this article we describe the protocol for the SIGGAR
trial, a randomised comparison of CTC against either
colonoscopy or barium enema. Participating radiologists
are members of SIGGAR, the Royal College of Radiolo-
gists Special Interest Group in Gastrointestinal and
Abdominal Radiology (now BSGAR, British Society of
Gastrointestinal and Abdominal Radiology [21]).
Research on this topic was commissioned by the UK
Health Technology Assessment (HTA) programme in
2002, who are funding the study (proposal 02/02/01).Trials 2007, 8:32 http://www.trialsjournal.com/content/8/1/32
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Study objectives
• To compare the detection rates and diagnostic sensitivity
for significant colorectal neoplasia of CTC versus barium
enema and CTC versus colonoscopy.
• To examine psychological and physical morbidity asso-
ciated with each diagnostic pathway.
• To determine costs of diagnosis associated with each
diagnostic pathway.
• To determine the frequency, clinical relevance, eco-
nomic costs, and psychological and physical morbidity
associated with detection of extracolonic lesions by CTC.
• To use data accumulated from the trial to populate mod-
els framed to summarise the health effects and costs of
alternative approaches to detection of significant colonic
neoplasia in patients of different ages, prior risks and pref-
erences.
Diagnostic pathway is defined by the procedure to which
the patient is initially randomised, recognising that some
patients will undergo more than one of the tests ('conver-
sion'), for example due to technical failure or to confirm
the result of the initial test.
Design and methods
General
The SIGGAR trial comprises two parallel prospective ran-
domised multicentre studies, each with a 2:1 randomisa-
tion in favour of the 'default' whole-colon examination
(Figure 1). One sub-trial compares CTC against colonos-
copy and the other CTC against barium enema. Recruit-
ment commenced April 2004.
Inclusion/exclusion criteria
Eligible patients are aged 55 years or older, able to give
informed consent, with symptoms or signs considered
suggestive of colorectal cancer by the referring physician
(e.g. change in bowel habit, rectal bleeding, abdominal
pain, anaemia). A decision to perform a "whole-colon"
examination to diagnose/exclude colorectal cancer will
have been taken by the clinician-in-charge and patients
must therefore be fit to undergo full bowel preparation.
Patients with a known genetic predisposition to cancer,
inflammatory bowel disease, or who are being followed-
up for colorectal cancer are excluded. They must have had
no "whole-colon" examination in the past six months.
Participating centres must have an established and effi-
cient fast-track clinical referral system for managing
patients referred with symptoms suggestive of colorectal
cancer, with a throughput sufficient to recruit at least 18
patients a month. Centres must also be able to satisfy
technical stipulations for the diagnostic interventions (see
section below). Participating centres were chosen fro
those interested in participating via a sham-randomisa-
tion procedure (see Discussion).
Ethical arrangements and consent
The SIGGAR trial achieved multi-centre ethical committee
(MREC) approval in January 2004 and is being conducted
in accordance with Medical Research Council guidelines
for good clinical practice in clinical trials and the Research
Governance Framework. Informed consent is a prerequi-
site. The trial is supervised by an independent data moni-
toring committee (DMC) and trial steering committee
(TSC) (see Acknowledgements).
Randomisation
Basic demographic and clinical information is collected
and patients registered at the time they are judged poten-
tially eligible for randomisation, usually by inspection of
referral forms/clinic letters in the days just prior to attend-
ance. Eligible, registered patients are then randomised
after agreement by the lead clinician and patient but data
relating to registered patients who are ultimately not ran-
domised are retained along with the reason for non-ran-
domisation, so that external validity can be judged and
estimates of generalisability made once the data are
known.
Randomisation is performed centrally, at the trial office.
Patients are randomised 2:1 in favour of the default diag-
Flow chart of patient recruitment to each sub-trial with sam- ple size for each group randomised Figure 1
Flow chart of patient recruitment to each sub-trial with sam-
ple size for each group randomised.
Adult patient with symptoms of
colorectal cancer and a clinical need
for a whole-colon examination.
Default examination
barium enema
Default examination
colonoscopy
Physician decides whether
barium enema or colonoscopy
most appropriate.
Randomisation Randomisation
Barium
enema
N = 2268
CT
colonography
N = 1134
CT
colonography
N = 477
Colonoscopy
N = 945Trials 2007, 8:32 http://www.trialsjournal.com/content/8/1/32
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nostic test (i.e. colonoscopy or barium enema). On the
advice of the DMC, details of stratification/blocks are con-
fidential since it is theoretically possible to predict alloca-
tion for some patients if past allocation and block site is
known.
Diagnostic interventions
1. CT colonography
CT colonography has undergone rapid technological evo-
lution since first described, which continues at the time of
writing. There have been particular advances in visualisa-
tion software. Because recruitment will take several years,
the protocol allows investigators to adopt advances dur-
ing the course of the trial so that findings are as up to data
as possible. The protocol for CTC is based on expert con-
sensus where this exists [22]. For example, multi-detector
row scanners are mandatory and patients must undergo
full bowel preparation, and both prone and supine scan-
ning at a minimum collimation of 2.5 mm. Where no
consensus exists, for example administration of intrave-
nous contrast and spasmolytic [23], local investigators
have freedom to choose in line with their personal prefer-
ence, which reflects normal clinical practice and enhances
generalisability. Interpretation software has been pro-
vided (Voxar, Barco, Anderson Place, Edinburgh, United
Kingdom, and V3D, Viatronix Inc, Stony Brook, NY), but
local investigators are free to use other commercially
available platforms according to their preference. Observ-
ers may use 2-D or 3-D reading, or any combination of the
two, reflecting individual preference in normal clinical
practice. Observers may report any colonic or extra-
colonic finding that they feel may explain patients' symp-
toms or which they consider potentially relevant, in line
with personal diagnostic thresholds. Interpretation is lim-
ited to consultant radiologists with a demonstrable sub-
specialist interest in gastrointestinal imaging (those
attending the gastrointestinal multi-disciplinary team
meetings for example), reflecting established practice for
investigation of symptomatic patients. All have previous
experience of CTC that has been supplemented with a
two-day training course for the purposes of the study. Trial
centres encompass both teaching and district general hos-
pitals to enhance generalisability.
2. Barium enema
Barium enema examinations are performed after full
bowel preparation, using best current practice; i.e. digital
fluoroscopy (512 matrix minimum) of the double-con-
trasted colorectum to the caecum, supplemented by over-
couch decubitus films. A spasmolytic and carbon dioxide
is used. Examinations are performed by either radiologists
with a subspecialty interest in gastrointestinal radiology
or radiographic technicians fully trained in barium enema
procedures, reflecting conventional practice. Enemas are
reported by radiologists with a subspecialty interest in gas-
trointestinal radiology.
3. Colonoscopy
Colonoscopy is performed by experienced colono-
scopists, either physicians or surgeons who have satisfied
stipulations on training made by the joint advisory group
on gastrointestinal endoscopy (JAG) [24]. Modern video-
endoscopes are used and sedation and analgesia adminis-
tered when judged clinically necessary in each individual
case. Colonoscopy to the caecum is intended initially in
all cases.
Datasheets for each diagnostic procedure are completed
by practitioners and detail clinical findings, procedural
information (quality of bowel preparation, completeness,
difficulty, diagnostic confidence, for example), any
adverse events, and data necessary to calculate resource
consumption subsequently.
We will obtain data for diagnosis of colorectal cancer for
randomised patients from the Office for National Statis-
tics (ONS) so that we have a denominator for calculation
of sensitivity in addition to detection rates by each diag-
nostic test.
Outcome measures
Primary outcome measures
1. CTC vs barium enema. Detection rates and diagnostic
sensitivity of significant colonic neoplasia by each test
2. CTC vs colonoscopy. Requirement for additional tests
needed to diagnose or exclude significant neoplasia.
Significant colorectal neoplasia is defined as cancer or
polyps 1 cm or larger. Such polyps may have a clinical
consequence for patients even if they are not the cause of
symptoms. We do not focus on detection rates in the
colonoscopy sub-trial because available evidence suggests
that colonoscopy and CT have equivalent sensitivity for
significant colorectal neoplasia.
Secondary outcome measures
• Time to diagnosis or exclusion of cancer for each diag-
nostic pathway. Time to diagnosis of pathology, if any,
responsible for the presenting symptoms.
• Frequency and nature of any adverse events split by diag-
nostic pathway.
• Technical adequacy for the different diagnostic proce-
dures; need for repeat procedures.
• Psychological reactions, adverse events, and preferences
for each diagnostic test. The precise outcomes to be meas-Trials 2007, 8:32 http://www.trialsjournal.com/content/8/1/32
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ured have been determined by a qualitative pilot study.
Interactions with collected demographic data (e.g. age,
gender, socio-economic status) and procedures (e.g.
number of procedures) will be assessed.
• Economic costs associated with different investigative
trajectories. Patient specific records of costs and outcomes
including the influence of conversion to other tests and
multiple investigations. Cost utility models to compare
management plans with outcome cost will be defined.
Test characteristics for CTC and patient preferences/qual-
ity of life measures will be combined with the economic
evaluation in order to determine overall cost utility.
• Modelling: A generic model will be developed to deter-
mine total effectiveness for each diagnostic pathway, pop-
ulated by outcomes from the trial data so that the findings
can be extrapolated beyond the trial. The model will pay
particular attention to the incidence, relevance, psycho-
logical reaction to, and costs of incidental extra-colonic
lesions detected by CTC.
Sample size
The initial sample size was calculated using the following
assumptions:
• Randomisation will be 2:1 in favour of the default diag-
nostic test (i.e. colonoscopy or barium enema).
• The prevalence of significant colorectal neoplasia (i.e.
cancer or polyps 1 cm or larger) in symptomatic adults is
approximately 15%.
• In each diagnostic pathway, additional examinations
will inevitably be required to diagnose or exclude cancer
in some patients. We assumed that the proportions
requiring further examinations are respectively 14% for
colonoscopy (based on anticipated completion rates),
20% for CTC (based on equivocal findings needing fur-
ther investigation, the need for polypectomy or biopsy in
those patients with neoplasia, and also those with signifi-
cant extracolonic findings needing further investigation),
and 15% for barium enema (based on need for further
investigation in those with polyps, false positive findings,
and incomplete examination in an elderly group, e.g due
to incontinence).
1. Diagnostic yield: CTC vs barium enema
The original sample size assumed a detection rate of sig-
nificant neoplasia of 15% for CTC and 10% for barium
enema. With a 2:1 randomisation in favour of barium
enema and an alpha of 0.05 (two-tailed), 2160 patients
gave us 90% power to detect a difference in detection
rates. A revised sample size was needed once the trial was
progressing as the above assumptions were found to be
overestimates (see Discussion). The revised sample size
assumed a detection rate of 7.5% for CTC and 5% for bar-
ium enema. To achieve 80% power to detect a difference
in detection rates with 2:1 randomisation in favour of bar-
ium enema and an alpha of 0.05 (two-tailed), 3402
patients were needed.
2. Subsequent colonic investigations: CTC vs colonoscopy
The available literature suggests that CTC and colonos-
copy are equivalent for diagnosis of cancer. A prevalence
of significant abnormality of only 15% means that a trial
at least ten times larger would be required to detect a diag-
nostic difference with reasonable power. In any event,
because such differences are likely to be small, the role of
CTC will instead turn on organisational factors, economic
costs, and on the personal reactions of patients. The
number of patients who need further investigations
before a diagnosis is made or refuted is central to this; the
"conversion rate". All the interventions tested will some-
times incur other tests, because of technical failure for
example, but the conversion rate is likely to be highest
with CTC because more structures are visualised than with
colonoscopy or barium enema.
Conversion rates of 20% for CTC and 14% for colonos-
copy were assumed. Assuming 2:1 randomisation in
favour of colonoscopy and an alpha of 0.05 (two-tailed),
an original sample size of 2160 provided 90% power to
detect a difference in conversion rates. As the trial pro-
gressed, it became apparent that recruitment to this sub-
trial was lower than anticipated. Power was lowered to the
more conventional 80% and retaining other assumptions
as above, the revised sample size was 1430.
Power calculations for psychological outcomes were
based on the Short form of the State Trait Anxiety Scale
(STAI). 4320 patients randomised overall (see sections
above) gave considerable overall power. However, our
findings need to be particularised to different settings and
subgroups so that the modelling exercise is accurate. We
therefore need adequate power in the smallest important
patient group – i.e. those needing further investigations
following CTC, including those with a positive diagnosis
of cancer (i.e. 20% of 720 + 720 = 288). This is sufficient
to give us 90% power to detect an 0.5 s.d. difference in
STAI scores whose mean value is 10.1 (s.d. 3.5), allowing
for a 20% questionnaire non-completion rate.
Analysis
The two sub-trials will be analysed as two separate case-
control studies. In each sub-trial, cases and controls will
be compared regarding covariates, including age, sex and
centre, using chi-squared or Fisher's exact test for categor-
ical variables and an unpaired t-test for continuous varia-
bles. The primary outcomes will be analysed usingTrials 2007, 8:32 http://www.trialsjournal.com/content/8/1/32
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multivariable logistic regression with study group as the
primary explanatory variable and adjustment for other
covariates, including age, sex and centre. Centre will be
considered as a random variable and the analysis will be
clustered on centre. Secondary outcomes will be analysed
using poisson regression for counts and logistic regression
for proportions with the same explanatory variables. The
data will be analysed in Stata 9.2 and variables will be
considered significant at the 5% level.
Discussion
Recruitment
At the time of writing (July 2007) 5025 patients have been
randomised; 3562 to the barium enema sub-trial and
1463 to the colonoscopy subtrial. Recruitment to the SIG-
GAR trial has gone well at a time when large randomised
trials of diagnostic interventions are finding it difficult to
reach their targets. Also, the trial does not obey the anec-
dotal "80:20 rule", which states that 80% of the work is
usually done at 20% of the centres; most of our centres are
recruiting well. We believe that there are several factors
that underpin this success, which others considering
implementing such a trial may find useful. Potential par-
ticipating centres were identified via expressions of inter-
est solicited through a UK-wide network of subspecialist
gastrointestinal radiologists (SIGGAR). This introduced a
spectrum bias towards interested subspecialists, who may
be more likely to participate actively in research. We had
identified CT scanner capacity as the main constraint on
patient accrual. Interested sites were therefore asked to
indicate potential CT capacity for the trial so that esti-
mates of the number of possible CT scans per year were
evidence-based, and powering was pragmatic. In particu-
lar, sample size can be achieved by either increasing the
number of centres or by more intense and prolonged
recruitment in fewer centres. We analysed the conse-
quences for participating hospitals in terms of 're-engi-
neering' their services for the trial in order to arrive at a
balance between the number of participating centres and
their marginal cost, arriving initially at the figure of 10
centres recruiting for 2-years.
Interested centres were also asked to perform a "sham-ran-
domisation" exercise both to prove that they could iden-
tify potential patients in sufficient numbers, and to focus
their attention on how this might be achieved. Over a
two-month period each centre was asked to identify
patients who satisfied trial inclusion criteria, record sim-
ple demographics for them (age, sex, symptoms, referral
route, and whole-colon investigation requested), and to
enter these on a secure, password-protected web-based
database. No patients were approached directly but this
"sham-randomisation" provided an evidence-based esti-
mate of how each centre might perform in reality, once
the trial was running. 25 centres registered for the sham
randomisation and the 10 best-performing were ulti-
mately selected (four of these had already been identified
as pilot sites because of extensive pre-existing familiarity
with CTC). We believe this procedure restricted participa-
tion to those centres most likely to recruit well in practice
and identified others in advance who would probably fare
poorly, thereby avoiding resource wastage. For example,
some centres who registered for the sham-randomisation
ultimately failed to register a single patient.
Trial procedures were also piloted extensively at a single
centre – 76 patients were randomised and a further 71 reg-
istered over 5 months before recruitment was rolled-out
to the centres selected by the sham-randomisation. Pilot-
ing identified efficient recruitment routes (for example, by
targeting outpatient clinics receiving most referrals),
tested trial materials, and allowed problems to be identi-
fied and solved at a single centre so that others joining
subsequently could benefit from procedures that had
already been proven to work in practice. For example, we
were able to develop strategies for dealing with partici-
pants who strongly desired allocation to CT colonogra-
phy, a problem we had not anticipated in advance. Roll-
out was implemented in a step-wise fashion, rather than
starting all other centres simultaneously. This allowed the
trial manager to concentrate on one or two new centres at
a time, and reduced the strain on the trial-office. All 10
centres had started recruiting by May 2005, approximately
one-year after the first pilot site. Other factors contribut-
ing to success have been the provision of funding suffi-
cient to purchase research sessions dedicated to the trial at
each centre, rather than relying upon the research nurses
who have to manage a portfolio of trials. We have also
hosted several investigator/collaborator meetings which
provide occasions for the principal investigators to praise
and motivate the centres. The meetings are also an excel-
lent opportunity for local investigators to share problems
and solutions in an informal setting.
Sample size assumptions
It is important to recognise that in a trial such as SIGGAR,
patients do not contribute to the primary end-point
unless they ultimately prove to have the target disease.
Centres with a low prevalence of cancer are therefore not
as effective as their recruitment suggests at first glance: It is
well recognised that the prevalence of disease in trials is
lower than would be expected normally. In such a situa-
tion it is important that the investigators and Data Moni-
toring Committee (DMC) continually reassess
recruitment in the light of the prevalence of abnormality.
An interim analysis carried out for the Trial Steering Com-
mittee Meeting in December 2005, at a time when 1237
patients had been randomised, noted that the prevalence
of abnormality was 7% overall, compared with the 10%
expected prior to the trial starting. Thus the trial hadTrials 2007, 8:32 http://www.trialsjournal.com/content/8/1/32
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accrued fewer end-points than anticipated. The prevalence
of abnormality also varied between sub-trials, being 12%
in the colonoscopy sub-trial but only 5% in the barium
enema sub-trial. Furthermore, although we had antici-
pated a 50:50 split between the two sub-trials, 862
(69.7%) had been recruited to the barium enema sub-trial
(where the prevalence of abnormality is lowest), and only
375 to the colonoscopy sub-trial. A request for extension
was made successfully, pointing out the need to increase
the numbers in the barium enema sub-trial above the
original sample size estimate while also increasing the rate
of recruitment to the colonoscopy sub-trial. Power was
also reduced from 90% to the more conventional 80%
overall. The original sample size of 4320 (2160 ran-
domised in each sub-trial) is now 4832, with 3402
patients needed in the barium enema sub-trial and 1430
in the colonoscopy sub-trial to acquire sufficient end-
points, taking into account the difference in disease prev-
alence between the two sub-trials. At the time of writing
5025 patients have been recruited and the trial is in a posi-
tion to close assuming that sufficient end-points have
been accrued.
One centre withdrew in 2005 following the recommenda-
tion of the Data Monitoring Committee. At the same time
a decision was made to extend recruitment to other cen-
tres in order to accelerate recruitment (see Appendix).
Increasing the number of centres was feasible because trial
procedures and materials had already been developed and
piloted, rolled-out, and were running efficiently at most
centres. Also, the marginal cost of a new centre was low
versus the cost of the trial as a whole. The decision to
implement new centres was taken only when effective
recruitment was established at existing centres; new cen-
tres would be very unlikely to enhance a trial that is failing
to recruit at existing centres. It is also vital to keep existing
centres motivated and ensure that the data are forthcom-
ing. We have exerted considerable effort on retrieving
completed data forms from centres.
Conclusion
The SIGGAR trial is a multi-centre randomised compari-
son of CT colonography against either barium enema or
colonoscopy. It aims to determine the diagnostic yield of
each test for significant colorectal neoplasia and to quan-
tify other aspects of diagnosis including patient accepta-
bility, adverse events, and costs. Excellent recruitment to
the SIGGAR trial to date demonstrates the benefits of a
sham-randomisation procedure used to select effective
centres, extensive piloting of materials and procedures,
and staged implementation of participating centres.
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